141 related articles for article (PubMed ID: 35232603)
1. Re: Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.003.
Wang Z; Zhao Y; Zhang Y
Eur Urol; 2022 May; 81(5):e120. PubMed ID: 35232603
[No Abstract] [Full Text] [Related]
2. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
Froehner M; Koch R; Thomas C
Eur Urol; 2020 Aug; 78(2):e91. PubMed ID: 32381458
[No Abstract] [Full Text] [Related]
3. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
Mollica V; Rizzo A; Massari F
Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
[No Abstract] [Full Text] [Related]
4. Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
Du J; Liu Y; Yan W
Eur Urol; 2020 Aug; 78(2):e64. PubMed ID: 32362499
[No Abstract] [Full Text] [Related]
5. Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
Wei Y; Zhang R; Lin L
Eur Urol; 2022 Sep; 82(3):e88. PubMed ID: 35750581
[No Abstract] [Full Text] [Related]
6. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
Singla N; Margulis V
Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
[No Abstract] [Full Text] [Related]
7. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
Noel J; Huillard O; Goldwasser F
Eur Urol; 2021 Apr; 79(4):e112. PubMed ID: 33518379
[No Abstract] [Full Text] [Related]
8. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
Chesnut GT; Vertosick EA; Ehdaie B
Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
[No Abstract] [Full Text] [Related]
9. Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
Eur Urol; 2021 Apr; 79(4):e113-e114. PubMed ID: 33487477
[No Abstract] [Full Text] [Related]
10. Re: Longbin Xiong, Jane K. Nguyen, Yulu Peng, et al. What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy? Eur Urol. 2022;81:492-500. https://doi.org/10.1016/j.eururo.2021.12.036.
Ren S; Zhong S; Fan S; Li X; Zhou F; Wang D
Eur Urol; 2022 Aug; 82(2):e49. PubMed ID: 35570147
[No Abstract] [Full Text] [Related]
11. Re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055: Standardized Reporting for Economic Analyses Should be Mandatory.
Castillo-Jimenez DA; García-Perdomo HA
Eur Urol; 2019 Jul; 76(1):e9. PubMed ID: 30665813
[No Abstract] [Full Text] [Related]
12. Re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006.
Ishiyama Y; Urabe F
Eur Urol; 2024 Apr; ():. PubMed ID: 38604930
[No Abstract] [Full Text] [Related]
13. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
[No Abstract] [Full Text] [Related]
14. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
Patel HD; Allaf ME
Eur Urol; 2013 Nov; 64(5):e105-6. PubMed ID: 23910939
[No Abstract] [Full Text] [Related]
15. Reply to Yudai Ishiyama and Fumihiko Urabe's Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006.
Takemura K; Yuasa T; Choueiri TK; Heng DYC
Eur Urol; 2024 Mar; ():. PubMed ID: 38531704
[No Abstract] [Full Text] [Related]
16. Reply to Diana A. Castillo-Jimenez and Herney A. García-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055. Standardized Reporting for Economic Analyses Should be Mandatory.
Sathianathen NJ; Konety BR
Eur Urol; 2019 Jul; 76(1):e10-e11. PubMed ID: 30665809
[No Abstract] [Full Text] [Related]
17. Re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020.
Höglund M;
Eur Urol; 2023 Aug; 84(2):e50. PubMed ID: 37268487
[No Abstract] [Full Text] [Related]
18. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.
Reig Torras O; Mishra A; Christie A; McKenzie T; Onabolu O; Singla N; Plimack ER; Suárez C; Ornstein MC; Alpaugh RK; Elias R; Bowman IA; McKay RM; Przybycin C; Kapur P; Brugarolas J; Rini B
Eur Urol; 2022 Jun; 81(6):555-558. PubMed ID: 34980496
[TBL] [Abstract][Full Text] [Related]
19. Re: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041.
Davies B; Kowalczyk K
Eur Urol; 2022 Jul; 82(1):e11. PubMed ID: 35428507
[No Abstract] [Full Text] [Related]
20. Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
Sun M; Karakiewicz PI; Trinh QD
Eur Urol; 2013 Nov; 64(5):e107-8. PubMed ID: 23910940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
